Aristides Capital’s Moderna MRNA Stock Holding History

Aristides Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,100	Closed	-$2.82M	–	253
2021 Q4	$2.82M	Buy	+11,100	New	+$3.25M	1.29%	17

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aristides Capital's MRNA Position: Q3 2025 in Review

Aristides Capital sold out of Moderna (MRNA) in Q3 2025, closing a stake of 20,000 shares — an estimated $552K sold.

Aristides Capital first reported a position in MRNA in Q1 2022 and held it in 3 quarters. The position peaked at $567K in Q1 2025. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

Aristides Capital reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
Aristides Capital sold 20,000 Moderna shares in Q3 2025, an estimated $552K.
Aristides Capital first reported a position in Moderna in Q1 2022 and held it in 3 quarters.
Aristides Capital's Moderna position peaked at $567K in Q1 2025.
643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Aristides Capital's 13F filing for Q3 2025, filed 13 Nov 2025.